Compare TG Therapeutics Inc (TGTX) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Advanced Drainage Systems Inc — how do they compare? TG Therapeutics Inc trades at $54.85 (market cap $8.16B), while Advanced Drainage Systems Inc trades at $125.42 (market cap $9.52B). The key difference: Advanced Drainage Systems Inc is the larger of the two by market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Advanced Drainage Systems Inc for 43 Days on average.
| TGTX | WMS | |
|---|---|---|
Market Cap | $8.16B | $9.52B |
Volume | 1,735,121 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $59.06 | $175.38 |
52-Week Low | $26.94 | $125.33 |
Typical Hold Time | 16 Days | 43 Days |
Enterprise Value | $8.37B | $11.12B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
WMS (Advanced Drainage Systems) trades at $124.92, down 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news includes the release of its 2026 Sustainability Report and a declared dividend of $0.20 per share payable in September 2026.
The outlook is supported by consistent earnings beats and analyst consensus pointing to significant upside with a $188.70 price target. However, a projected negative net cash flow of -$473M for 2026 and bearish technical indicators present near-term risks. Investor sentiment is mixed amid institutional buying and selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
